Economic Burden and Unmet Need Among Adult Patients With Varying Patterns of Atopic Dermatitis: Results From the Adelphi Real-World Disease Specific Program
Author(s)
Jonathan I. Silverberg, MD, PhD, MPH1, Alexis Sohn, MPH, MS, PharmD2, Kimberly M Deininger, PhD, MPH2, Joyce Qian, PhD, MPH, MS3, Oliver Howell, BSc4, Corey Moorhead, BSc4, Emily Quinones, BSc4, James Piercy, MSc, PhD4.
1Department of Dermatology, The George Washington University School of Medicine and Health Sciences, Washington, DC, USA, 2Amgen Inc., Thousand Oaks, CA, USA, 3Kyowa Kirin Inc. 510 Carnegie Center, Suite 600, Princeton, NJ, USA, 4Adelphi Real World, Bollington, United Kingdom.
1Department of Dermatology, The George Washington University School of Medicine and Health Sciences, Washington, DC, USA, 2Amgen Inc., Thousand Oaks, CA, USA, 3Kyowa Kirin Inc. 510 Carnegie Center, Suite 600, Princeton, NJ, USA, 4Adelphi Real World, Bollington, United Kingdom.
OBJECTIVES: Characterize patients with atopic dermatitis (AD) with the highest economic and patient-reported burden over a 12-month (12mo) period across US/Europe (France/Germany/Italy/Spain/United Kingdom).
METHODS: Data were drawn from the Adelphi AD Disease Specific ProgrammeTM, a cross-sectional survey, with retrospective data collection of physicians and their patients with AD in US/Europe collected August 2022-April 2024. We specifically analysed physician-reported patient demographics, clinical status 12mo prior to and at data collection (currently), current treatment, and healthcare resource utilisation (HCRU) including consultations/tests over the last 12mo. Patients reported work productivity/activity impairment (WPAI), NRS-Itch (range 0-10, higher score worse) and NRS-Sleep (range 0-10, lower score worse). Latent class analysis identified distinct patient groups based on disease pattern and clinical status 12mo prior.
RESULTS: Analysis included 675 physicians and 1,114 patients (mean age [SD] 37.4[13.7] years). Patients clustered into four groups. Notable differences between groups were: those who flare only (F) 17.9%, those with day-to-day symptoms only (D) 21.7%, and those with mixed flaring and day-to-day symptoms. Mixed groups further differed by IGA scores 12mos prior with predominantly moderate IGA (FD-M) 45.6%, or predominantly severe IGA (FD-S) 14.8%. FD-S and FD-M had higher mean number of consultations/tests over the 12mos (FD-S, 5.1/13.0; FD-M, 4.3/11.0, respectively), whereas F and D had 3.7/8.8 and 3.8/9.9 consultations/tests, respectively. Currently, 75.2% FD-S and 65.3% FD-M patients were receiving advanced systemic therapy (AST - biologic/oral JAK inhibitor) vs F (28.8%), and D (57.9%). FD-S reported 23.7%/32.4% overall work/activity impairment, FD-M reported 23.4%/25.9%, compared with 18.8%/22.6% and 15.4%/22.5% for F and D respectively. Despite high HCRU, 30.5% FD-S /21.5% FD-M currently still have moderate-to-severe IGA, NRS-itch scores of 5.2/4.4, and NRS-sleep of 6.5/7.4.
CONCLUSIONS: Patients experiencing mixed flaring and day-to-day symptoms demonstrated higher HCRU and AST use. Yet, these patients still experience remaining unmet clinical needs, as reflected in WPAI and ongoing disease/symptom burden.
METHODS: Data were drawn from the Adelphi AD Disease Specific ProgrammeTM, a cross-sectional survey, with retrospective data collection of physicians and their patients with AD in US/Europe collected August 2022-April 2024. We specifically analysed physician-reported patient demographics, clinical status 12mo prior to and at data collection (currently), current treatment, and healthcare resource utilisation (HCRU) including consultations/tests over the last 12mo. Patients reported work productivity/activity impairment (WPAI), NRS-Itch (range 0-10, higher score worse) and NRS-Sleep (range 0-10, lower score worse). Latent class analysis identified distinct patient groups based on disease pattern and clinical status 12mo prior.
RESULTS: Analysis included 675 physicians and 1,114 patients (mean age [SD] 37.4[13.7] years). Patients clustered into four groups. Notable differences between groups were: those who flare only (F) 17.9%, those with day-to-day symptoms only (D) 21.7%, and those with mixed flaring and day-to-day symptoms. Mixed groups further differed by IGA scores 12mos prior with predominantly moderate IGA (FD-M) 45.6%, or predominantly severe IGA (FD-S) 14.8%. FD-S and FD-M had higher mean number of consultations/tests over the 12mos (FD-S, 5.1/13.0; FD-M, 4.3/11.0, respectively), whereas F and D had 3.7/8.8 and 3.8/9.9 consultations/tests, respectively. Currently, 75.2% FD-S and 65.3% FD-M patients were receiving advanced systemic therapy (AST - biologic/oral JAK inhibitor) vs F (28.8%), and D (57.9%). FD-S reported 23.7%/32.4% overall work/activity impairment, FD-M reported 23.4%/25.9%, compared with 18.8%/22.6% and 15.4%/22.5% for F and D respectively. Despite high HCRU, 30.5% FD-S /21.5% FD-M currently still have moderate-to-severe IGA, NRS-itch scores of 5.2/4.4, and NRS-sleep of 6.5/7.4.
CONCLUSIONS: Patients experiencing mixed flaring and day-to-day symptoms demonstrated higher HCRU and AST use. Yet, these patients still experience remaining unmet clinical needs, as reflected in WPAI and ongoing disease/symptom burden.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EE354
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies, Work & Home Productivity - Indirect Costs
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c.), Hematological Disorders (non-oncologic), Pain)